FDA approved "Intermezzo" for insomnia characterized by sudden sleeplessness during midnight

The U.S. Food and Drug Administration (FDA) approved "Intermezzo" (zolpidem tartrate sublingual tablets) for use as required to care for insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.   This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of bedtime remaining....

HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference

HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Confere...

Pfizer to Acquire Excaliard Pharmaceuticals - Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals

Excaliard’s lead product, EXC 001, an antisense oligonucleotide in phase 2, is designed to interrupt the process of fibrosis by inhibiting expression of connective tissue growth factor (CTGF). CTGF is a growth factor that can be over expressed in damaged skin or tissue following surgery or traumatic injury and lead to disfiguring skin scarring. The phase 2 program for EXC 001 has thus far produced...

India's New Drug pricing policy will cost Rs 4,000 crore revenue loss to drug makers - Pharmaceutical News India

India's New Drug pricing policy will cost Rs 4,000 crore revenue loss to drug makers  The proposed national drug pricing policy will cost drugmakers approximately 1,500 crore and stockists and traders collectively over 2,500 crore in revenue loss when it comes into effect. While drugmaker GlaxoSmithKline Pharmaceuticals loss has been pegged at 137 crore, that of Ranbaxy Laboratories...

Drugmakers’ Returns on Research decline with Pipeline Projects Fail - Drug Maker's News - Pharmaceutical News

The top drugmakers saw falls on their investments in new products decline 29 % from last year (2010) as more experimental drugs failed at unaffordable belated levels of development, according to a report. Pharmaceutical-company returns on research and development fell by 3.4 % points to 8.4 % this year, the report by consulting firm Deloitte LLP found. The study considered the 12 drugmakers that spend the most on R&D, including New York-based...

Biotech's largest expenders 2011 - Biotechnology News - Biopharma News for 2011

Biotechnology Article based on Pharmabiz (Source) If you add up the R&D budgets for the top 15 public biotechs in the world, you will discover a tab that runs right about $10 billion. That's not chickenfeed, by hook or by crook, but to put it in some position, it is interesting to note that Roche, which has the largest research budget for any biopharma on the planet, spent a bit more than that...

Stem Cell Scientist talks about New Drug evolution Process

Pharmaceutical companies should address stem cells for a more effective and cost-efficient way to try out with new medications, Harvard professor Lee L. Rubin said in a presentation yesterday. Rubin, who is the Stem Cell and Regenerative Biological science professor and a director at the Harvard Stem Cell Institute, said that because stem cells mimic the biological environment of the human body,...